In PCa, inhibition of CPT1A (the liver isoform of CPT1) reduces viability of LNCaP and VCaP cells and tumors [18], and increases PCa sensitivity to the anti-androgen enzalutamide [19,20]. This evidence concerns the gene CPT1A and posterior cortical atrophy.